Assetmark Inc. Has $109.31 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Assetmark Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,980 shares of the biopharmaceutical company’s stock after purchasing an additional 8,289 shares during the period. Assetmark Inc. owned approximately 0.09% of Regeneron Pharmaceuticals worth $109,308,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.48% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on REGN. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Guggenheim upped their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,092.62.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $828.42 on Friday. The firm has a fifty day simple moving average of $1,021.70 and a 200 day simple moving average of $1,036.38. The company has a market capitalization of $91.04 billion, a PE ratio of 20.50, a P/E/G ratio of 3.12 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $783.57 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.